<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631057</url>
  </required_header>
  <id_info>
    <org_study_id>1160.254</org_study_id>
    <nct_id>NCT02631057</nct_id>
  </id_info>
  <brief_title>Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan</brief_title>
  <official_title>Comparison of the Length of Stay in Patients Hospitalized and Initiated With Dabigatran or Warfarin for a Concomitant Non-Valvular Atrial Fibrillation in Real-world Japanese Therapeutic Practice (SHORT-J)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the Length of Stay from treatment of oral
      anticoagulant initiation to hospital discharge of patients hospitalized and subsequently
      treated with dabigatran or warfarin for non-valvular atrial fibrillation in a real-world
      Japanese clinical practice. The secondary objective of the study is to compare LoS of
      patients hospitalized with 1) acute ischemic stroke, and 2) due to non-valvular atrial
      fibrillation. Other objectives are (1) to compare the in-hospital direct and indirect-related
      costs between dabigatran and warfarin, and (2) to compare the rates of patients directly
      discharged at home after the index hospitalization between dabigatran and warfarin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2016</start_date>
  <completion_date type="Actual">September 7, 2016</completion_date>
  <primary_completion_date type="Actual">September 7, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Length of Stay (LoS) From Treatment of Oral Anticoagulant Initiation to Hospital Discharge Without Consideration of Baseline</measure>
    <time_frame>From the date of index treatment until the date of discharge from hospital, assessed upto 60 months.</time_frame>
    <description>The outcome measure presents LoS from initiation of treatment with oral anticoagulants to hospital discharge without consideration of baseline of patients hospitalized for any reason, who were subsequently treated with Dabigatran or Warfarin for a NVAF.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">4313</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Non-Valvular Atrial Fibrillation</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>acute ischemic stroke</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Dabigatran 110 mg capsule twice a day or 75 mg x 2 capsules twice a day</description>
    <arm_group_label>Non-Valvular Atrial Fibrillation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Warfarin tablet (adjustment by each patients)</description>
    <arm_group_label>acute ischemic stroke</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Japan
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Hospitalized patients among patients having a visit record with a confirmed diagnosis of
        NVAF (ICD-10 Code: I48) and prescribed dabigatran or warfarin in the hospitalization period

        Exclusion criteria:

          1. Having a record with a diagnosis of atrial flutter, valvular atrial fibrillation or
             postoperative atrial fibrillation diagnosis as standard disease name during the study
             period.

          2. Having a record with a diagnosis of rheumatic atrial fibrillation (ICD-10 code I05 to
             I09 [chronic rheumatic atrial fibrillation])or mechanical-valvular atrial fibrillation
             (ICD-10 code T820 [artificial cardiac valve mechanical complication]) during the study
             period.

          3. Having a record with a confirmed diagnosis of cancer (ICD-10 code C00-C97 [malignant
             neoplasm]) during the study period.

          4. Having a record of dialysis (class J038 artificial kidney) during the study period.

          5. Having a record of dabigatran use for a purpose other than prevention of ischemic
             stroke and systemic embolism in non-valvular atrial fibrillation patients.

          6. Having a record of dabigatran or warfarin before the hospitalization

          7. Having a record of new diagnosis of atrial fibrillation after the initiation of
             dabigatran or warfarin treatment in the hospitalization period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.254.81001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NISED Center</name>
      <address>
        <city>Tokyo, Shinagawa</city>
        <zip>1416017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2015</study_first_posted>
  <results_first_submitted>August 30, 2017</results_first_submitted>
  <results_first_submitted_qc>August 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2018</results_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dabigatran Etexilate [Prazaxa®]</title>
          <description>The patients were administered Dabigatran Etexilate 75 mg*2 mg capsules twice daily or 110 mg capsules twice daily orally for Non-Valvular Atrial Fibrillation (NVAF).</description>
        </group>
        <group group_id="P2">
          <title>Warfarin</title>
          <description>Dose-adjusted Warfarin for several days to reach an effective International Normalized Ratio (INR) for ischemic stroke prevention due to NVAF.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="899"/>
                <participants group_id="P2" count="3414"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="899"/>
                <participants group_id="P2" count="3414"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis set included patients who received the treatment Dabigatran Etexilate [Prazaxa®] or Warfarin.</population>
      <group_list>
        <group group_id="B1">
          <title>Dabigatran Etexilate [Prazaxa®]</title>
          <description>The patients were administered Dabigatran Etexilate 75 mg*2 mg capsules twice daily or 110 mg capsules twice daily orally for Non-Valvular Atrial Fibrillation (NVAF).</description>
        </group>
        <group group_id="B2">
          <title>Warfarin</title>
          <description>Dose-adjusted Warfarin for several days to reach an effective International Normalized Ratio (INR) for ischemic stroke prevention due to NVAF.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="899"/>
            <count group_id="B2" value="3414"/>
            <count group_id="B3" value="4313"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="11.6"/>
                    <measurement group_id="B2" value="76.1" spread="10.4"/>
                    <measurement group_id="B3" value="74.9" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="1398"/>
                    <measurement group_id="B3" value="1695"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="602"/>
                    <measurement group_id="B2" value="2016"/>
                    <measurement group_id="B3" value="2618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Length of Stay (LoS) From Treatment of Oral Anticoagulant Initiation to Hospital Discharge Without Consideration of Baseline</title>
        <description>The outcome measure presents LoS from initiation of treatment with oral anticoagulants to hospital discharge without consideration of baseline of patients hospitalized for any reason, who were subsequently treated with Dabigatran or Warfarin for a NVAF.</description>
        <time_frame>From the date of index treatment until the date of discharge from hospital, assessed upto 60 months.</time_frame>
        <population>The analysis set included patients who received the treatment Dabigatran Etexilate [Prazaxa®] or Warfarin.</population>
        <group_list>
          <group group_id="O1">
            <title>Dabigatran Etexilate [Prazaxa®]</title>
            <description>The patients were administered Dabigatran Etexilate 75 mg*2 mg capsules twice daily or 110 mg capsules twice daily orally for Non-Valvular Atrial Fibrillation (NVAF).</description>
          </group>
          <group group_id="O2">
            <title>Warfarin</title>
            <description>Dose-adjusted Warfarin for several days to reach an effective International Normalized Ratio (INR) for ischemic stroke prevention due to NVAF.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay (LoS) From Treatment of Oral Anticoagulant Initiation to Hospital Discharge Without Consideration of Baseline</title>
          <description>The outcome measure presents LoS from initiation of treatment with oral anticoagulants to hospital discharge without consideration of baseline of patients hospitalized for any reason, who were subsequently treated with Dabigatran or Warfarin for a NVAF.</description>
          <population>The analysis set included patients who received the treatment Dabigatran Etexilate [Prazaxa®] or Warfarin.</population>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="899"/>
                <count group_id="O2" value="3414"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="13.5"/>
                    <measurement group_id="O2" value="14.9" spread="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Abadie-Imbens</method>
            <method_desc>LoS Average Treatment Effect on the Treated (ATET) [Dabigatran group], dispersion analysed with Abadie-Imbens’s standard error.</method_desc>
            <param_type>Mean</param_type>
            <param_value>-2.484</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.629</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.717</ci_lower_limit>
            <ci_upper_limit>-1.251</ci_upper_limit>
            <estimate_desc>The ATET of LoS from oral anticoagulant initiation to hospital discharge was calculated as [Dabigatran – Warfarin] in the matched cohort of matching ratio 1:3.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious and other (non-serious) adverse events were not of interest in this study and therefore were not collected or assessed as part of the study, in addition individual patient data is not available therefore adverse event data is not presented.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dabigatran Etexilate [Prazaxa®]</title>
          <description>The patients were administered Dabigatran Etexilate 75 mg*2 mg capsules twice daily or 110 mg capsules twice daily orally for Non-Valvular Atrial Fibrillation (NVAF).</description>
        </group>
        <group group_id="E2">
          <title>Warfarin</title>
          <description>Dose-adjusted Warfarin for several days to reach an effective International Normalized Ratio (INR) for ischemic stroke prevention due to NVAF.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

